484 related articles for article (PubMed ID: 11121142)
1. Elimination of CD4(+) T cells enhances anti-tumor effect of locally secreted interleukin-12 on B16 mouse melanoma and induces vitiligo-like coat color alteration.
Nagai H; Hara I; Horikawa T; Oka M; Kamidono S; Ichihashi M
J Invest Dermatol; 2000 Dec; 115(6):1059-64. PubMed ID: 11121142
[TBL] [Abstract][Full Text] [Related]
2. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.
Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M
Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effects on mouse melanoma elicited by local secretion of interleukin-12 and their enhancement by treatment with interleukin-18.
Nagai H; Hara I; Horikawa T; Fujii M; Kurimoto M; Kamidono S; Ichihashi M
Cancer Invest; 2000; 18(3):206-13. PubMed ID: 10754989
[TBL] [Abstract][Full Text] [Related]
4. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
[TBL] [Abstract][Full Text] [Related]
5. Murine B16 melanoma vaccination-induced tumor immunity: identification of specific immune cells and functions involved.
Wu TY; Fleischmann WR
J Interferon Cytokine Res; 2001 Dec; 21(12):1117-27. PubMed ID: 11798470
[TBL] [Abstract][Full Text] [Related]
6. Tumor-localized ligation of CD3 and CD28 with systemic regulatory T-cell depletion induces potent innate and adaptive antitumor responses.
Lee CH; Chiang YH; Chang SE; Chong CL; Cheng BM; Roffler SR
Clin Cancer Res; 2009 Apr; 15(8):2756-66. PubMed ID: 19318495
[TBL] [Abstract][Full Text] [Related]
7. [The mechanism of anti-tumor immune response against mouse melanoma to xenogeneic vaccination].
Luo F; Mao YQ; Kan B; He QM; Jiang Y; Peng F; Yang L; Tian L
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Nov; 35(6):757-60. PubMed ID: 15573746
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor.
Björkdahl O; Dohlsten M; Sjögren HO
Cancer Gene Ther; 2000 Oct; 7(10):1365-74. PubMed ID: 11059695
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma.
Oniki S; Nagai H; Horikawa T; Furukawa J; Belladonna ML; Yoshimoto T; Hara I; Nishigori C
Cancer Res; 2006 Jun; 66(12):6395-404. PubMed ID: 16778218
[TBL] [Abstract][Full Text] [Related]
10. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes.
Søndergaard H; Galsgaard ED; Bartholomaeussen M; Straten PT; Odum N; Skak K
J Immunother; 2010 Apr; 33(3):236-49. PubMed ID: 20445344
[TBL] [Abstract][Full Text] [Related]
12. Gene transfer of secreted-type modified interleukin-18 gene to B16F10 melanoma cells suppresses in vivo tumor growth through inhibition of tumor vessel formation.
Nagai H; Hara I; Horikawa T; Oka M; Kamidono S; Ichihashi M
J Invest Dermatol; 2002 Sep; 119(3):541-8. PubMed ID: 12230493
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of interleukin-15 in vivo enhances antitumor activity against MHC class I-negative and -positive malignant melanoma through augmented NK activity and cytotoxic T-cell response.
Yajima T; Nishimura H; Wajjwalku W; Harada M; Kuwano H; Yoshikai Y
Int J Cancer; 2002 Jun; 99(4):573-8. PubMed ID: 11992548
[TBL] [Abstract][Full Text] [Related]
14. The opposite effect of tumor-infiltrating natural killer cells on in vivo priming of tumor-specific CD8+ T cells and CD4+ T cells.
Terao H; Harada M; Kurosawa S; Shinomiya Y; Ito O; Tamada K; Takenoyama M; Nomoto K
Immunobiology; 1996 Jul; 195(2):172-86. PubMed ID: 8877394
[TBL] [Abstract][Full Text] [Related]
15. Induction of cellular immunity against hair follicle melanocyte causes alopecia.
Nagai H; Oniki S; Oka M; Horikawa T; Nishigori C
Arch Dermatol Res; 2006 Aug; 298(3):131-4. PubMed ID: 16786344
[TBL] [Abstract][Full Text] [Related]
16. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma.
Li Y; McGowan P; Hellström I; Hellström KE; Chen L
J Immunol; 1994 Jul; 153(1):421-8. PubMed ID: 7515929
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity.
Seo N; Hayakawa S; Takigawa M; Tokura Y
Immunology; 2001 Aug; 103(4):449-57. PubMed ID: 11529935
[TBL] [Abstract][Full Text] [Related]
18. B16 cell lysates plus polyinosinic-cytidylic acid effectively eradicate melanoma in a mouse model by acting as a prophylactic vaccine.
Lin B; Zhao H; Fan J; Xie F; Wang W; Ding X
Mol Med Rep; 2014 Aug; 10(2):911-6. PubMed ID: 24840631
[TBL] [Abstract][Full Text] [Related]
19. Breakdown of Th cell immune responses and steroidogenic CYP11A1 expression in CD4+ T cells in a murine model implanted with B16 melanoma.
Oka H; Emori Y; Hayashi Y; Nomoto K
Cell Immunol; 2000 Nov; 206(1):7-15. PubMed ID: 11161433
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-18 gene transfer increases antitumor effects of suicide gene therapy through efficient induction of antitumor immunity.
Ju DW; Yang Y; Tao Q; Song WG; He L; Chen G; Gu S; Ting CC; Cao X
Gene Ther; 2000 Oct; 7(19):1672-9. PubMed ID: 11083476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
